NeuroSense Therapeutics is a clinical-stage drug development company focused on addressing the unmet needs of patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company is pioneering a combined therapeutic approach that targets multiple mechanisms involved in these complex conditions. Their lead product, PrimeC, is a unique formulation that combines two FDA-approved drugs, ciprofloxacin and celecoxib, designed to synergistically inhibit ALS progression by regulating microRNA synthesis, reducing neuroinflammation, and managing iron accumulation. PrimeC has successfully completed a phase 2a clinical trial and is preparing for a pivotal phase 2b/3 study, with additional recognition including orphan drug designation from both the U.S. FDA and the European Medicines Agency.

In addition to ALS, NeuroSense is expanding its research pipeline to include potential treatments for Alzheimer’s and Parkinson’s diseases. The company is leveraging the shared biological pathways among these neurodegenerative diseases to develop new therapies. For Alzheimer’s, they are testing a candidate named CogniC in preclinical models, while for Parkinson’s, they are exploring a drug called StabiliC. This strategic focus on combined therapies and the exploration of relevant biomarkers underscores NeuroSense's commitment to innovating treatment options for patients suffering from these debilitating conditions.

United States

Advancing research, development and therapy for ALS and additional CNS indications.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.

Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.

NeuroSense Therapeutics

Company Details